$ZNTL
Zentalis Pharmaceuticals, Inc. Stock $zntl

$zntl Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000172516023000155 Filed on August 09, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$15.95M	$15.66M	$19.64M
YoY Change	32.81%	-20.23%	89.5%
% of Gross Profit
Research & Development	$46.77M	$42.68M	$43.83M
YoY Change	10.87%	-2.6%	-2.11%
% of Gross Profit
Depreciation & Amortization	$348.0K	$344.0K	$348.0K
YoY Change	-7.2%	-1.15%	192.44%
% of Gross Profit
Operating Expenses	$62.72M	$103.9M	$63.46M
YoY Change	15.73%	63.75%	15.11%
Operating Profit	-$62.72M	-$103.9M	-$63.46M
YoY Change	15.73%	63.75%	15.11%
Interest Expense	$7.209M	$4.451M	$424.0K
YoY Change	278.43%	949.76%	268.7%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$55.51M	-$99.47M	-$63.04M
YoY Change	6.16%	57.79%	14.58%
Income Tax	$31.00K	-$605.0K	$17.00K
% Of Pretax Income
Net Earnings	-$55.53M	-$112.5M	-$68.36M
YoY Change	2.07%	64.62%	25.26%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.79	-$1.85	-$1.34
Diluted Earnings Per Share	-$0.79	-$1.85	-$1.337M
COMMON SHARES
Basic Shares Outstanding	70.61M shares	59.48M shares	46.63M shares
Diluted Shares Outstanding	70.61M shares	60.79M shares	51.12M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$516.6M	$553.0M	$455.2M
YoY Change	22.51%	21.48%	81.44%
Cash & Equivalents	$110.8M	$266.6M	$55.14M
Short-Term Investments	$405.9M	$286.4M	$400.1M
Other Short-Term Assets	$9.696M	$9.133M	$12.41M
YoY Change	-20.29%	-26.38%	45.19%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$528.3M	$563.9M	$467.6M
YoY Change	21.75%	20.59%	80.24%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.393M	$6.650M	$51.52M
YoY Change	-20.36%	-87.09%	2188.89%
Goodwill	$3.736M	$3.736M
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00	$30.41M
YoY Change	-100.0%	-100.0%
Other Assets	$11.14M	$10.55M	$14.57M
YoY Change	-13.38%	-27.6%	70.73%
Total Long-Term Assets	$57.45M	$57.52M	$100.2M
YoY Change	-39.72%	-42.62%	308.89%
TOTAL ASSETS
Total Short-Term Assets	$528.3M	$563.9M	$467.6M
Total Long-Term Assets	$57.45M	$57.52M	$100.2M
Total Assets	$585.7M	$621.4M	$567.9M
YoY Change	10.68%	9.44%	99.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$14.26M	$12.31M	$12.04M
YoY Change	45.25%	2.19%	45.55%
Accrued Expenses	$44.65M	$39.45M	$35.90M
YoY Change	0.93%	9.9%	41.88%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$58.92M	$51.76M	$48.64M
YoY Change	8.98%	6.42%	44.85%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.634M	$2.376M	$45.07M
YoY Change	-96.38%	-94.73%	15127.03%
Total Long-Term Liabilities	$1.634M	$2.376M	$45.07M
YoY Change	-96.38%	-94.73%	15127.03%
TOTAL LIABILITIES
Total Short-Term Liabilities	$58.92M	$51.76M	$48.64M
Total Long-Term Liabilities	$1.634M	$2.376M	$45.07M
Total Liabilities	$103.8M	$98.16M	$95.37M
YoY Change	3.35%	2.93%	162.33%
SHAREHOLDERS EQUITY
Retained Earnings	-$827.6M	-$772.1M
YoY Change	52.87%
Common Stock	$70.00K	$70.00K
YoY Change	22.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$481.8M	$523.1M	$472.5M
YoY Change
Total Liabilities & Shareholders Equity	$585.7M	$621.4M	$567.9M
YoY Change	10.68%	9.44%	99.98%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$55.53M	-$112.5M	-$68.36M
YoY Change	2.07%	64.62%	25.26%
Depreciation, Depletion And Amortization	$348.0K	$344.0K	$348.0K
YoY Change	-7.2%	-1.15%	192.44%
Cash From Operating Activities	-$38.66M	-$79.27M	-$43.03M
YoY Change	16.46%	84.24%	-6.69%
INVESTING ACTIVITIES
Capital Expenditures	$90.00K	$319.0K	-$278.0K
YoY Change	-105.42%	-214.75%	-65.89%
Acquisitions
YoY Change
Other Investing Activities	-$117.4M	$73.25M	-$141.8M
YoY Change	-641.37%	-151.65%	-310.34%
Cash From Investing Activities	-$117.4M	$72.93M	-$142.1M
YoY Change	-686.71%	-151.32%	-313.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	313.0K	236.6M	209.5M
YoY Change	-46.86%	12.97%	-66383.23%
NET CHANGE
Cash From Operating Activities	-38.66M	-79.27M	-43.03M
Cash From Investing Activities	-117.4M	72.93M	-142.1M
Cash From Financing Activities	313.0K	236.6M	209.5M
Net Change In Cash	-155.8M	230.3M	24.33M
YoY Change	1137.28%	846.56%	20.6%
FREE CASH FLOW
Cash From Operating Activities	-$38.66M	-$79.27M	-$43.03M
Capital Expenditures	$90.00K	$319.0K	-$278.0K
Free Cash Flow	-$38.75M	-$79.59M	-$42.75M
YoY Change	22.87%	86.19%	-5.63%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	91000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	266558000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55143000	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	2627000	usd
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	2627000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	385665000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13342000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	218000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	235680000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	941000	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-37000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-112527000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	523282000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	434024000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	27075000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1015000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	235680000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	941000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	373000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	209297000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	158000	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-35000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-68357000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	472823000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	364482000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	26911000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1654000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	209297000	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	803000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	612000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-195000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-127434000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	472823000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</span></div>
CY2023Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-13700000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	286766000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	40000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	378000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	286428000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	395655000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	71000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1424000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	394302000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	42	security
CY2023Q2	us-gaap	Trading Securities Debt TradingSecuritiesDebt	193700000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	400000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	38	security
CY2023Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	400000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	4	security
CY2023Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	25900	usd
CY2023Q2	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Fair Value HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue	264470000	usd
CY2023Q2	zntl	Foreign Research And Development Credit Refund ForeignResearchAndDevelopmentCreditRefund	911000	usd
CY2022Q4	zntl	Foreign Research And Development Credit Refund ForeignResearchAndDevelopmentCreditRefund	659000	usd
CY2023Q2	zntl	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	13872000	usd
CY2022Q4	zntl	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	15002000	usd
CY2023Q2	us-gaap	Interest Receivable InterestReceivable	878000	usd
CY2022Q4	us-gaap	Interest Receivable InterestReceivable	508000	usd
CY2023Q2	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	932000	usd
CY2022Q4	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Fair Value HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue	394302000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	21958000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	0	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	286428000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	394302000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	261994000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	286428000	usd
CY2023Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	548422000	usd
CY2023Q2	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	500000	usd
CY2023Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	500000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	28809000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	394302000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	423111000	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	0	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	0	usd
CY2023Q2	us-gaap	Prepaid Insurance PrepaidInsurance	1322000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1018000	usd
CY2023Q2	zntl	Prepaid Software License And Maintenance PrepaidSoftwareLicenseAndMaintenance	574000	usd
CY2022Q4	zntl	Prepaid Software License And Maintenance PrepaidSoftwareLicenseAndMaintenance	958000	usd
CY2022Q4	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	0	usd
CY2023Q2	us-gaap	Other Receivables OtherReceivables	0	usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables	5874000	usd
CY2023Q2	zntl	Other Prepaid Expense OtherPrepaidExpense	372000	usd
CY2022Q4	zntl	Other Prepaid Expense OtherPrepaidExpense	266000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	18861000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	24285000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	7918000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	9723000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10943000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14562000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9414000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9765000	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2764000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2060000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6650000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7705000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	704000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	692000	usd
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.85
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.85
CY2023Q2	zntl	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	28783000	usd
CY2022Q4	zntl	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	32310000	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7992000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11246000	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	602000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1256000	usd
CY2023Q2	zntl	Accrued General And Administrative Costs Current AccruedGeneralAndAdministrativeCostsCurrent	996000	usd
CY2022Q4	zntl	Accrued General And Administrative Costs Current AccruedGeneralAndAdministrativeCostsCurrent	662000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2335000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2162000	usd
CY2023Q2	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	500000	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	0	usd
CY2023Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	622000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	384000	usd
CY2023Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	41830000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	48020000	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2376000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2620000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	39454000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	45400000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	27075000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26911000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	27075000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26911000	usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	51500	shares
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	73500	shares
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	3257000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6486000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6799000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	7278000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	7451000	usd
CY2023Q2	zntl	Lessee Operating Lease Liability To Be Paid Due After Year Four LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour	38778000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	70049000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	23687000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	46362000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2335000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44027000	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y3M18D
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	5000000.0	usd
	us-gaap	Sublease Income SubleaseIncome	200000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-175746000	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60790000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60790000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48197000	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.64
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11626000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8522000	shares
CY2023Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
0001725160-23-000155-index-headers.html	Edgar Link	pending
0001725160-23-000155-index.html	Edgar Link	pending
0001725160-23-000155.txt	Edgar Link	pending
0001725160-23-000155-xbrl.zip	Edgar Link	pending
exh101-recuriumxzenoxthird.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
zentalis10-qq22023ex311.htm	Edgar Link	pending
zentalis10-qq22023ex312.htm	Edgar Link	pending
zentalis10-qq22023ex321.htm	Edgar Link	pending
zentalis10-qq22023ex322.htm	Edgar Link	pending
zntl-20230630.htm	Edgar Link	pending
zntl-20230630.xsd	Edgar Link	pending
zntl-20230630_g1.jpg	Edgar Link	pending
zntl-20230630_def.xml	Edgar Link	unprocessable
zntl-20230630_lab.xml	Edgar Link	unprocessable
zntl-20230630_pre.xml	Edgar Link	unprocessable
zntl-20230630_htm.xml	Edgar Link	completed
zntl-20230630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ZNTL
Zentalis Pharmaceuticals, Inc. Stock $zntl

2023 Q3 Form 10-Q Financial Statement

#000172516023000155 Filed on August 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZNTL Zentalis Pharmaceuticals, Inc. Stock $zntl

2023 Q3 Form 10-Q Financial Statement

#000172516023000155 Filed on August 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZNTL
Zentalis Pharmaceuticals, Inc. Stock $zntl